QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
NASDAQ:CTIC

CTI BioPharma - CTIC Stock Forecast, Price & News

$4.44
+0.07 (+1.60%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.39
$4.53
50-Day Range
$4.30
$6.01
52-Week Range
$3.32
$7.80
Volume
2.34 million shs
Average Volume
3.02 million shs
Market Capitalization
$585.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

CTI BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.2% Upside
$10.67 Price Target
Short Interest
Bearish
12.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of CTI BioPharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.78 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

614th out of 999 stocks

Pharmaceutical Preparations Industry

299th out of 489 stocks


CTIC stock logo

About CTI BioPharma (NASDAQ:CTIC) Stock

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Stock News Headlines

CTI BioPharma (NASDAQ:CTIC) Trading Up 4.4%
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
CTIC CTI BioPharma Corp.
CTIC.OQ - | Stock Price & Latest News | Reuters
CTI BioPharma to Present at Upcoming November Conferences
CTI BioPharma: Q3 Earnings Snapshot
CTI BioPharma's VONJO May Be Coming Of Age
See More Headlines
Receive CTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CTIC Company Calendar

Last Earnings
3/06/2023
Today
3/29/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTIC
Previous Symbol
NASDAQ:CTICD
Employees
22
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+140.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-92,990,000.00
Net Margins
-172.37%
Pretax Margin
-172.37%

Debt

Sales & Book Value

Annual Sales
$53 million
Book Value
($0.14) per share

Miscellaneous

Free Float
118,389,000
Market Cap
$585.37 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Adam R. CraigAdam R. Craig
    President, CEO, Director & Chief Medical Officer
  • David H. Kirske
    Chief Financial Officer & Executive Vice President
  • Jim Fong
    Chief Commercial Officer & Executive VP
  • John Volpone
    Senior Vice President-Strategic Operations













CTIC Stock - Frequently Asked Questions

Should I buy or sell CTI BioPharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTIC shares.
View CTIC analyst ratings
or view top-rated stocks.

What is CTI BioPharma's stock price forecast for 2023?

6 equities research analysts have issued twelve-month target prices for CTI BioPharma's shares. Their CTIC share price forecasts range from $9.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for CTIC
or view top-rated stocks among Wall Street analysts.

How have CTIC shares performed in 2023?

CTI BioPharma's stock was trading at $6.01 at the start of the year. Since then, CTIC stock has decreased by 26.1% and is now trading at $4.44.
View the best growth stocks for 2023 here
.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 15,970,000 shares, an increase of 18.3% from the February 28th total of 13,500,000 shares. Based on an average daily volume of 2,950,000 shares, the days-to-cover ratio is currently 5.4 days.
View CTI BioPharma's Short Interest
.

When is CTI BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CTIC earnings forecast
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) posted its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to analyst estimates of $24.88 million. CTI BioPharma had a negative trailing twelve-month return on equity of 5,105.50% and a negative net margin of 172.37%. During the same period last year, the company posted ($0.38) earnings per share.

When did CTI BioPharma's stock split?

Shares of CTI BioPharma reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (3.89%), Lion Point Capital LP (2.92%), Geode Capital Management LLC (1.51%), Point72 Asset Management L.P. (1.39%), Schonfeld Strategic Advisors LLC (1.38%) and Verition Fund Management LLC (1.15%). Insiders that own company stock include Adam R Craig, Bvf Partners L P/Il, David Kirske, James K Fong, Michael A Metzger and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of CTI BioPharma?

Shares of CTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $4.44.

How much money does CTI BioPharma make?

CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $585.37 million and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206.

This page (NASDAQ:CTIC) was last updated on 3/29/2023 by MarketBeat.com Staff